MS drug Lemtrada investigators protest FDA decision

[MSUK]

Several multiple sclerosis (MS) experts who were involved in the clinical development program for alemtuzumab (Lemtrada, Genzyme) have voiced their disappointment and frustration over the recent decision by the US Food and Drug Administration (FDA) not to approve the drug.

Stephen Krieger, MD, from Mount Sinai Medical Center, New York; Edward Fox, MD, from the Multiple Sclerosis Clinic of Central Texas, Round Rock; and Jeffrey Cohen, MD, from Cleveland Clinic, Ohio, all told Medscape Medical News that they strongly disagree with the FDA decision and are worried about the consequences, which could include patients sourcing the drug from other countries but not being monitored for the serious safety issues.... Read More - http://www.ms-uk.org/index.cfm/lemtrada

[ChrisDeMuthJr]

The FDA Nixes a Pathbreaking Drug for MS: http://online.wsj.com/news/articles/SB1 ... #printMode